Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Interventional Radiology(Electronic Edition) ›› 2024, Vol. 12 ›› Issue (04): 311-316. doi: 10.3877/cma.j.issn.2095-5782.2024.04.004

• Monographic Study·Respiratory Intervention • Previous Articles     Next Articles

Clinical efficacy and safety analysis of bronchial artery chemoembolization with drug-loaded microspheres in the treatment of refractory non-small cell lung cancer

Wei Cui1, Suyi Ye2, Yi Deng2, Xiaoming Chen1, Jing Zhang1, Jing Li2,3,(), Rongde Xu1,()   

  1. 1.Department of InterventionalRadiology,Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences),Southern Medical University,Guangdong Guangzhou 510080
    2.Department of Pulmonary and Critical Care Medicine,The First People's Hospital of Yunnan Province,Medical School of Kunming University of Science and Technology,Yunnan Kunming 650093,China
    3.Department of Pulmonary and Critical Care Medicine,Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences),Southern Medical University,Guangdong Guangzhou 510080
  • Received:2024-07-04 Online:2024-11-25 Published:2024-12-19
  • Contact: Jing Li, Rongde Xu

Abstract:

Objective

To investigate the clinical efficacy and safety of drug-loaded microspheres bronchial artery chemoembolization (D-BACE) in treating refractory non-small cell lung cancer (NSCLC).

Methods

A retrospective analysis was conducted on 17 patients with stage Ⅲ~Ⅳ refractory NSCLC underwent D-BACE combined with systemic treatment (chemotherapy, targeted therapy, immunotherapy)from June 2018 to December 2022. The number of D-BACE treatments, median progression-free survival(PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and safety were recorded.

Results

The median number of D-BACE treatments was 1, ranging from 1 to 7 times. The ORR was 17.6%, and the DCR was 64.7%. The OS was 19.0 months, and the PFS was 9.5 months. No severe complications were observed; mild complications included chest numbness in 5 cases (29.4%), pain in 8 cases (47.0%), and nausea and vomiting in 5 cases (29.4%).

Conclusion

D-BACE combined with systemic treatment can effectively control refractory NSCLC with minor adverse reactions, warranting further exploration and promotion.

Key words: Refractory non-small cell lung cancer, Drug-eluting beads, Bronchial arterial chemo embolization, Interventional radiology

京ICP 备07035254号-20
Copyright © Chinese Journal of Interventional Radiology(Electronic Edition), All Rights Reserved.
Tel: 0756-2528259 E-mail: zhjrfsx@163.com
Powered by Beijing Magtech Co. Ltd